⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452517 | 0.81 | — | — | |
| SCHEMBL4779258 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL6602988 | 0.79 | LMNA (0.51) | — | |
| SCHEMBL22262919 | 0.77 | MAPT (0.46) | — | |
| Bromide SCHEMBL6170869 | 0.77 | MAPT (0.42) | — | |
| SCHEMBL13545146 | 0.76 | MAPT (0.45) | — | |
| SCHEMBL12292649 | 0.76 | LMNA (0.57) | — | |
| SCHEMBL11538083 | 0.76 | ATM (0.48) | — | |
| SCHEMBL11276698 | 0.76 | LMNA (0.57) | — | |
| SCHEMBL13543211 | 0.76 | ALDH1A1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295236-A1 | COMPOUNDS FOR USE IN INFLAMMATORY CONDITIONS | PHARMA MAR, S.A. (ES) | 2023-09-21 | — | — | US | disclosed |
| WO-2021175826-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | PHARMA MAR, S.A. (ES) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021175857-A1 | COMPOUNDS FOR USE IN INFLAMMATORY CONDITIONS | PHARMA MAR, S.A. (ES) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021175831-A2 | COMPOUNDS FOR USE IN VIRAL INFECTIONS | PHARMA MAR, S.A. (ES) | 2021-09-10 | — | — | WO | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-9326973-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| EP-1737876-B1 | AVERMECTIN AND AVERMECTIN MONOSACCHARIDE SUBSTITUTED IN THE 4\"-AND 4'-POSITION RESPECTIVELY | SYNGENTA PARTICIPATIONS AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| EP-1536797-B1 | 1-AMIDO-4-PHENYL-4-BENZYLOXYMETHYL-PIPERIDINE DERIVATIVES AND RELATED COMOUNDS AS NEUROKININ-1 (NK-1) ANTAGONSISTS FOR THE TREATMENT OF EMESIS, DEPRESSION, ANXIETY AND COUGH | SCHERING CORP (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7176214-B2 | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1045833-B1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6608070-B1 | Useful for treatment of medical condition in which prostaglandins are implicated as pathogens | NAKAO KAZUNARI (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1045833-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035130-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-15 | — | — | WO | disclosed |